Navigation Links
Synthetic Biologics Reports Year End 2012 Financial Results
Date:4/16/2013

ROCKVILLE, Md., April 16, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the year ended December 31, 2012 and summarized recent operational highlights.

Operational Highlights:Expanding Infectious Disease Portfolio

  • C. difficile Infections:
  • Utilizing our portfolio of beta-lactamase enzymes we acquired in November 2012, we intend to develop a proprietary oral beta-lactamase enzyme product candidate, SYN-004 (formerly Ipsat P3A), for the prevention of C. difficile infections (CDI). When co-administered with certain intravenous (IV) beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the gastrointestinal (GI) tract, thus preserving the natural balance of the patient's microflora, and preventing opportunistic infections including CDI and antibiotic-associated diarrhea (AAD).
  • Animal studies of P1A (the first generation candidate) showed that C. difficile colonization and disease could be prevented in mouse models and that colonization by resistant bacteria could also be prevented. P1A was shown to be safe and well tolerated in a Phase I study. In addition, two Phase II clinical studies demonstrated that P1A had the ability to preserve GI microflora in hospitalized patients treated with IV ampicillin or the combination of piperacillin and tazobactam.
  • Compared to P1A, we believe that SYN-004 will have activity against a broader spectrum of beta-lactam antibiotics, including both penicillins and most cephalosporins.
  • According to GlobalData, an estimated 8.7 million Americans were administered IV beta-lactam antibiotics in 2011.
  • Pertussis:
  • In December 2012, in collaboration with Intrexon Corporation (Intrexon), we initiated development of a
    '/>"/>

  • SOURCE Synthetic Biologics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
    2. Synthetic Biologics to Present at the 25th Annual ROTH Conference
    3. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
    4. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
    5. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
    6. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
    7. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
    8. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
    9. Synthetic Biologics Reports Second Quarter 2012 Financial Results
    10. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
    11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... Sept. 19, 2014  The board of directors of ... quarterly cash dividend of $0.42 per share.  ... to stockholders of record at the close of business ... is a global, research-based biopharmaceutical company formed in 2013 ... use its expertise, dedicated people and unique approach to ...
    (Date:9/19/2014)... 19, 2014 Merck (NYSE: MRK ), known ... Canada , is teaming with celebrity chef and ... Tus Metas , an educational program encouraging Hispanics with type 2 ... key treatment goal to help reduce the risk of serious health ... at a higher risk for developing type 2 diabetes than non-Hispanic ...
    (Date:9/19/2014)... , Sept. 19, 2014 Larry J. ... CVS ), will speak before the National Press Club ... discuss the company,s recent move to stop selling tobacco products ... the future of health. "Dramatic changes in our ... care providers and government," Merlo has said. "CVS Health has ...
    Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
    ... 23 DuPont (NYSE: DD ) and ... joint venture to develop, manufacture and commercialize advanced surgical ... venture will be named Actamax Surgical Materials LLC. Under ... share a 50 percent interest. The joint venture ...
    ... Precision Therapeutics announced today that President and Chief ... Magazine 2010 Pacesetters Award.  The award honors thirteen ... influence in the community-at-large as well as within ... Tuesday, September 21st at the Kean Theatre in ...
    Cached Medicine Technology:DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 3DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 4Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award 2
    (Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
    (Date:9/19/2014)... 9/18/14) A leading Dartmouth researcher, working with The Melanoma ... paper published today in the Journal of the ... the risk of melanoma. , "For the first time, ... of these telomeres play a part in the risk ... Mark Iles, PhD, School of Medicine at the University ...
    (Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
    (Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
    (Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
    Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
    ... 6 Cowen Group, Inc. (Nasdaq: COWN ) ... a Senior Analyst covering managed care and health care service ... covered health care services stocks from 1999 to 2008. ... the lead analyst covering healthcare services. Between 2000 and ...
    ... 6 Prism Pharmaceuticals, Inc.,announced today that Dr. Warren ... the 27th Annual J.P. Morgan Healthcare Conference on,Tuesday, January ... a.m. (Eastern,Time). The conference will be held at ... Dr. Cooper will present corporate ...
    ... SMTS ) will release its financial results for ... before the opening of the market on,Wednesday, January 21, ... will host a conference call that will be webcast ... On the conference call, Bruce Barrett, ...
    ... at Home Depot saw big increase in employees working out ... to work out works, a new study says. , ... to support workers in setting exercise goals notably increased their ... The findings were published in the February edition of ...
    ... Design Creates Tangible Value by Revealing New Revenue ... LLC, a firm that specializes in designing customer-centric ... for growth-oriented companies, today announced its official launch. ... build and launch new services around business opportunities ...
    ... Population is Undertreated When Compared to California, According ... Mass., Jan. 6 Decision Resources, one of ... on pharmaceutical and healthcare issues, finds that Florida ... the Alzheimer,s disease drug market despite the large ...
    Cached Medicine News:Health News:Cowen Adds Health Care Service Analyst to Equity Research Department 2Health News:Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009 2Health News:Employer-Sponsored Workouts Boost Workers' Health 2Health News:First Service Design Firm Launches in United States 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 3
    Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
    Epilation forceps straight ends size 3.5"....
    Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
    Forceps, extra delicate, straight....
    Medicine Products: